GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.
about
The Antibody Response against HIV-1Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus MacaquesThe Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cellsRecombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41.Transcytosis of HIV-1 through vaginal epithelial cells is dependent on trafficking to the endocytic recycling pathway.The role of dendritic cells in driving genital tract inflammation and HIV transmission risk: are there opportunities to intervene?Vaginal myeloid dendritic cells transmit founder HIV-1.Interactions between HIV-1 and mucosal cells in the female reproductive tractMucosal correlates of protection in HIV-1-exposed sero-negative persons.Stromal down-regulation of macrophage CD4/CCR5 expression and NF-κB activation mediates HIV-1 non-permissiveness in intestinal macrophagesHIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesLive simian immunodeficiency virus vaccine correlate of protection: local antibody production and concentration on the path of virus entry.Expression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1.Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.HIV is inactivated after transepithelial migration via adult oral epithelial cells but not fetal epithelial cells.Use of human mucosal tissue to study HIV-1 pathogenesis and evaluate HIV-1 prevention modalities.Rapid SIV Env-specific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge.HIV-1 envelope glycan moieties modulate HIV-1 transmission.Early HIV-1 target cells in human vaginal and ectocervical mucosaIs developing an HIV-1 vaccine possible?Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women.Immunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.Strategies for eliciting HIV-1 inhibitory antibodiesInfectious virion capture by HIV-1 gp120-specific IgG from RV144 vaccineesMicrobicides: still a long road to successNeutralizing IgG at the portal of infection mediates protection against vaginal simian/human immunodeficiency virus challengeIntestinal macrophages and response to microbial encroachment.Epitope specificity of human immunodeficiency virus-1 antibody dependent cellular cytotoxicity [ADCC] responses.Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection.Identification of Human Anti-HIV gp160 Monoclonal Antibodies That Make Effective Immunotoxins.A heterologous prime-boosting strategy with replicating Vaccinia virus vectors and plant-produced HIV-1 Gag/dgp41 virus-like particles.Broadly neutralizing antibodies suppress post-transcytosis HIV-1 infectivity.Neutralizing antibodies in patients with chronic hepatitis C and correlation to liver cirrhosis and estimated duration of infection.Topological analysis of HIV-1 glycoproteins expressed in situ on virus surfaces reveals tighter packing but greater conformational flexibility than for soluble gp120.Challenges of antibody-mediated protection against HIV-1.The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages.Increasing the Clinical Potential and Applications of Anti-HIV Antibodies.Human Intestinal Epithelial Cells Release Antiviral Factors That Inhibit HIV Infection of Macrophages.Functional characterization of the recombinant HIV-neutralizing monoclonal antibody 2F5 produced in maize seeds
P2860
Q27000889-97BD6493-2E59-47FD-9A3B-D33CC4399C61Q27318508-32E883CA-D46D-4504-B850-6DBF27C0F279Q28302792-C404996D-211D-4CAF-816D-F4098A65C679Q30601090-55C4EC0B-2216-458C-ADC5-DBD3AC55A04CQ33618602-DACA2F0E-D7D4-477B-BA67-A851842E83A7Q33662836-DF189F5E-4CDA-4981-8350-B780390E11FAQ33744037-82D3626E-FEED-4D9E-839E-C351D586FB09Q33815410-00E00C76-5040-4DB6-B78A-153F9688369DQ33911540-E24656F9-60D2-4027-A7EB-5B3F8376B893Q33921277-6C4CD6D7-F6DC-460B-BAF6-F09650C55AC1Q33939974-EEA845C5-1413-4917-830C-DF3660F81FE9Q34146728-FE67050E-E396-476E-A52D-16B984D15328Q34242643-A5FD6031-98F6-4054-BA22-3A7BAB112C76Q34283442-35977C59-56D3-4B77-AECE-4FBA644B0E96Q34554611-8C519C5C-6A57-40DA-9996-9D2D79F8A703Q34566597-1DD477DF-F256-408B-96C1-7E2054487D09Q34574409-7C4199A6-A040-4BA4-9A7B-3D5DFA97B91EQ34595009-91ED7700-1F30-4C5B-A541-3C964B378097Q34796617-94FF5081-DEAB-463D-B348-9983D7504144Q35043547-FBFB9D48-3DDE-4989-BA28-E39B1948B188Q35093052-202DEB1D-3141-44C9-B2F0-04D08EAD00B6Q35872338-688B52A5-63E1-48CB-A5D5-D3C7C769F4AFQ35960908-3B820E55-491E-456C-914F-03FC0E9167A1Q36452155-35019A8F-1E2E-4486-B1D9-2CCB758C9060Q36978671-7D45E0E9-7DBD-47E2-BCC2-32084E0E66A0Q37130757-27327E04-98EC-4FBA-BBFA-8EC06157D733Q37252676-B12EDAE0-414D-49F1-A8C4-2B9B11D7AA4CQ37292224-07E52D10-BE28-4732-81E5-9E83D656F4CDQ37426168-0D6A059A-5DB8-4E96-B43A-57A9D278700FQ37510242-17AF07AB-B0B3-4F53-8BE9-7D6651D03CB0Q37593177-2CFAB9C9-7235-4808-A553-6964CA457188Q40220988-A09E1F41-1262-4976-8779-B8D25F11127AQ40410573-0D6AA07B-D4FD-48B2-A05F-755473215A41Q40736190-CE08D9C7-08B5-4EFF-8D94-57F64D799027Q42572387-BC6C7AC0-27B6-41F7-8E5E-F48EB6344D30Q42679187-39CD103B-0BAB-4888-8D24-9F0EC05944EEQ45719125-F052A6A6-934B-4377-AA33-23F56C500A18Q47110966-A9C5CEA2-85C2-47C1-94BE-21939869A2D1Q54260280-C2299AC4-25DD-4C03-81A1-A0D93D51E6A2Q57522803-76F0871F-201F-466C-9910-15E163A88CD4
P2860
GP41-specific antibody blocks cell-free HIV type 1 transcytosis through human rectal mucosa and model colonic epithelium.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 March 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
GP41-specific antibody blocks ...... and model colonic epithelium.
@en
GP41-specific antibody blocks ...... and model colonic epithelium.
@nl
type
label
GP41-specific antibody blocks ...... and model colonic epithelium.
@en
GP41-specific antibody blocks ...... and model colonic epithelium.
@nl
prefLabel
GP41-specific antibody blocks ...... and model colonic epithelium.
@en
GP41-specific antibody blocks ...... and model colonic epithelium.
@nl
P2093
P2860
P356
P1476
GP41-specific antibody blocks ...... a and model colonic epithelium
@en
P2093
Christina Ochsenbauer
Daniela Tudor
Diane Bimczok
Ernesto R Drelichman
Jamie A Cannon
John C Kappes
Lesley E Smythies
Phillip D Smith
Ruizhong Shen
P2860
P304
P356
10.4049/JIMMUNOL.0903346
P407
P577
2010-03-05T00:00:00Z